Kailera Therapeutics (Nasdaq: KLRA) filed for an initial public offering of 33,333,334 shares of common stock at a price range of USD 14.00 to USD 16.00 per share, targeting a listing on the Nasdaq Global Select Market.
At the midpoint of the range, the offering would raise approximately USD 500 million in gross proceeds before discounts and commissions. Underwriters hold a 30-day option to purchase up to 5,000,000 additional shares at the offering price. Existing stockholders, including entities affiliated with Bain Capital Private Equity, Bain Capital Life Sciences, and Qatar Investment Authority, provided non-binding indications of interest to purchase up to an aggregate of approximately USD 225 million in shares at the initial public offering price on the same terms as other purchasers. The filing did not disclose post-offering ownership percentages.
Kailera Therapeutics is a clinical-stage biotechnology company developing four GLP-1-based product candidates for obesity, all licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive development and commercialization rights outside of Greater China. The lead asset, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist currently being evaluated in the KaiNETIC global Phase III program, comprising three trials initiated between December 2025 and January 2026, with topline results expected in 2028. The pipeline also includes an oral tablet formulation of ribupatide, the oral small molecule GLP-1 receptor agonist KAI-7535, and the GLP-1/GIP/glucagon receptor tri-agonist KAI-4729. In addition to the four clinical-stage candidates, Kailera also has the first refusal rights on certain other metabolic assets in development by Hengrui.